Page 11 - Read Online

Page 6 of 7 Pelizzaro et al. Hepatoma Res 2021;7:36 https://dx.doi.org/10.20517/2394-5079.2021.24

J Med 2018;379:54-63. DOI PubMed PMC
8. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
9. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-
fetoprotein concentrations ( REACH-2 ): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-96.
DOI PubMed
10. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med
2020;382:1894-905. DOI PubMed
11. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellula carcinoma: ASCO Guideline. J Clin
Oncol 2020;38:4317-45. DOI PubMed
12. Yau T, Park JW, Finn RS, et al. LBA38_PR - CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs
sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30
(suppl_5):v874-5. DOI
13. Finn RS, Ryoo BY, Merle P, et al; KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202. DOI
PubMed
14. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable
hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8. DOI PubMed PMC
15. Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single - agent bevacizumab therapy in patients with
advanced hepatocellular carcinoma. Oncologist 2012;17:1063-72. DOI PubMed PMC
16. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther
2009;9:503-9. DOI PubMed
17. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol
2011;8:292-301. DOI PubMed PMC
18. Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and vegf inhibitors in advanced hepatocellular
carcinoma. Cancers (Basel) 2020;12:1089. DOI PubMed PMC
19. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: Opportunities
and challenges. Nat Rev Clin Oncol 2018;15:325-40. DOI PubMed PMC
20. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to
immune escape. Front Immunol 2012;3:21. DOI PubMed PMC
21. Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014;4:70. DOI
PubMed PMC
22. Lee MS, Ryoo BY, Hsu CH, et al; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular
carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020;21:808-20. DOI PubMed
23. Sonbol MB, Riaz I Bin, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a
systematic review and network meta-analysis. JAMA Oncol 2020;6:e204930. DOI PubMed PMC
24. Casak SJ, Donoghue M, Fashoyin-Aje L, et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients
with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res 2020;27:1836-41. DOI PubMed
25. Giannini EG, Aglitti A, Borzio M, et al; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview
of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to
immune checkpoint inhibitors in clinical practice. Cancers (Basel) 2019;11:1689. DOI PubMed PMC
26. Tovoli F, De Lorenzo S, Trevisani F. Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: where are we now?
Vaccines (Basel) 2020;8:578. DOI PubMed PMC
27. Alsina A, Kudo M, Vogel A, et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc
responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer 2020;9:93-104. DOI
PubMed PMC
28. Zhu AX, Finn RS, Edeline J, et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52. DOI
PubMed
29. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-
label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. DOI PubMed PMC
30. Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The
GIDEON study. J Hepatol 2016;65:1140-7. DOI PubMed
31. Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for patients with hepatocellular
carcinoma and Child-Pugh B liver cirrhosis: lessons learned from a terminated study. Oncologist 2020;25:e1274-9. DOI PubMed
PMC
32. McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular
carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. DOI PubMed
33. Chen SC, Chao Y, Chen MH. Lenvatinib for the treatment of HCC: A single institute experience. J Clin Oncol 2019;37:e15611. DOI
34. Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma
analysis of REACH trial results by child-pugh score. JAMA Oncol 2017;3:235-43. DOI PubMed